AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34356647 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic abdominal swabs
Number of subjects: 0
Study 34356647 — intervention group
Group type: COMPARATOR
Intervention: Cotton abdominal swabs
Number of subjects: 0
Study 32006325 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycolated exenatide injection (PB-119) at doses of 2-200 µg
Number of subjects: 70
Study 32006325 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycolated exenatide injection (PB-119) at doses of 25-400 µg
Number of subjects: 70
Study 32006325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 616996472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg twice daily
Number of subjects: 22
Study 616996472 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 100 mg alone
Number of subjects: 22
Study 616996472 — intervention group
Group type: EXPERIMENTAL
Intervention: Pridopidine 90 mg single dose
Number of subjects: 22
Study 32063079 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intralesional triamcinolone acetonide (TA) and platelet rich plasma (PRP)
Number of subjects: 40
Study 32063079 — intervention group
Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (TA) alone
Number of subjects: 40
Study 34724955 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Management Training (pGMT)
Number of subjects: 76
Study 34724955 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducative control (paediatric Brain Health Workshop, pBHW)
Number of subjects: 76
Study 35553192 — intervention group
Group type: EXPERIMENTAL
Intervention: tVNSab (transcutaneous vagal nerve stimulation applied to the auricle branch of the vagus nerve)
Number of subjects: 7
Study 35553192 — intervention group
Group type: EXPERIMENTAL
Intervention: tVNSab
Number of subjects: 7
Study 33851905 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative opioid counseling (5-minute pre-recorded standardized video)
Number of subjects: 107
Study 33851905 — intervention group
Group type: COMPARATOR
Intervention: Control group (no counseling)
Number of subjects: 107
Study 36081136 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli program during soccer training
Number of subjects: 38
Study 36081136 — intervention group
Group type: COMPARATOR
Intervention: Regular soccer training program alone
Number of subjects: 38
Study 32434381 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFreedom stent
Number of subjects: 3151
Study 32434381 — intervention group
Group type: COMPARATOR
Intervention: Orsiro stent
Number of subjects: 3151
Study 33657754 — intervention group
Group type: EXPERIMENTAL
Intervention: MST to non-paralytic dorsiflexion muscles (n=11)
Number of subjects: 21
Study 33657754 — intervention group
Group type: COMPARATOR
Intervention: MST to paralytic dorsiflexion muscles (n=10)
Number of subjects: 21
Study 34902050 — intervention group
Group type: EXPERIMENTAL
Intervention: High GI rice (GI: 79)
Number of subjects: 212
Study 34902050 — intervention group
Group type: COMPARATOR
Intervention: Medium GI rice (GI: 64)
Number of subjects: 212
Study 33165774 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 120 mg TID for 1 day
Number of subjects: 28
Study 33165774 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 240 mg TID for 1 day
Number of subjects: 28
Study 33165774 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 120 mg TID for 14 days
Number of subjects: 28
Study 33165774 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2982772 240 mg TID for 14 days
Number of subjects: 28
Study 33165774 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID for 1 day
Number of subjects: 28
Study 33165774 — intervention group
Group type: COMPARATOR
Intervention: Placebo TID for 14 days
Number of subjects: 28
Study 32014029 — intervention group
Group type: EXPERIMENTAL
Intervention: Doll Therapy Intervention
Number of subjects: 128
Study 32014029 — intervention group
Group type: COMPARATOR
Intervention: Sham Intervention
Number of subjects: 128
Study 33942506 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous heterogeneous skin construct
Number of subjects: 50
Study 33942506 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment
Number of subjects: 50
Study 33631359 — intervention group
Group type: EXPERIMENTAL
Intervention: WL + weighted vest use (WL + VEST)
Number of subjects: 192
Study 33631359 — intervention group
Group type: COMPARATOR
Intervention: WL alone
Number of subjects: 192
Study 33631359 — intervention group
Group type: COMPARATOR
Intervention: WL + RT
Number of subjects: 192
Study 36441560 — intervention group
Group type: EXPERIMENTAL
Intervention: Etripamil 70 mg
Number of subjects: 156
Study 36441560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 33140199 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenomedullin (AM) at 15 ng/kg/min
Number of subjects: 28
Study 33140199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 35101082 — intervention group
Group type: EXPERIMENTAL
Intervention: Community dialogue approach
Number of subjects: 0
Study 32894122 — intervention group
Group type: EXPERIMENTAL
Intervention: Free healthy school meal for one year
Number of subjects: 164
Study 35489024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 256
Study 35489024 — intervention group
Group type: COMPARATOR
Intervention: Control (chemotherapy without bevacizumab)
Number of subjects: 256
Study 34743721 — intervention group
Group type: EXPERIMENTAL
Intervention: WW (formerly Weight Watchers) for 12‐weeks
Number of subjects: 1267
Study 34743721 — intervention group
Group type: EXPERIMENTAL
Intervention: WW (formerly Weight Watchers) for 52‐weeks
Number of subjects: 1267
Study 34743721 — intervention group
Group type: EXPERIMENTAL
Intervention: WW mobile app
Number of subjects: 1267
Study 34743721 — intervention group
Group type: EXPERIMENTAL
Intervention: Study visits at 3‐, 12‐, 24‐, and 60‐months
Number of subjects: 1267
Study 35443365 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) program
Number of subjects: 120
Study 35443365 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DSME)
Number of subjects: 120
Study 34530286 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right auditory cortex
Number of subjects: 41
Study 34530286 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS over the right auditory cortex
Number of subjects: 41
Study 32573284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored physiotherapy intervention
Number of subjects: 42
Study 33743851 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg in two 150 mg tablets twice daily)
Number of subjects: 295
Study 33743851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295
Study 33743851 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 295
Study 34710550 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Active Compression-Decompression CPR (ACD-CPR)
Number of subjects: 210
Study 34710550 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete AD in > 50% of OUs
Number of subjects: 210
Study 34710550 — intervention group
Group type: COMPARATOR
Intervention: Standard Mechanical CPR (Control)
Number of subjects: 210
Study 33237565 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago exercise program
Number of subjects: 72
Study 33237565 — intervention group
Group type: COMPARATOR
Intervention: Walking program (control)
Number of subjects: 72
Study 35538754 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant bovine basic fibroblast growth factor gel
Number of subjects: 120
Study 35538754 — intervention group
Group type: COMPARATOR
Intervention: Control group (Erythromycin ointment)
Number of subjects: 120
Study 33238898 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care (CC) by trained maternity care assistants (MCAs) during labor
Number of subjects: 992
Study 33238898 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 992
Study 33238898 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous care (CC)
Number of subjects: 992
Study 35412513 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 210
Study 35412513 — intervention group
Group type: COMPARATOR
Intervention: No-pill control (NPC)
Number of subjects: 210
Study 35412513 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo (DBP)
Number of subjects: 210
Study 32232943 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless spinal cord stimulation (SCS) system
Number of subjects: 12
Study 32646565 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge bleeding events (GUSTO moderate, severe, or life-threatening bleeding)
Number of subjects: 45011
Study 32646565 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge myocardial infarction (MI)
Number of subjects: 45011
Study 32646565 — intervention group
Group type: COMPARATOR
Intervention: Participants treated with PCI
Number of subjects: 45011
Study 32646565 — intervention group
Group type: COMPARATOR
Intervention: Participants treated without PCI
Number of subjects: 45011
Study 33417699 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical Bayesian model for drug response in cancer cell lines
Number of subjects: 0
Study 33417699 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional randomization testing procedure
Number of subjects: 0
Study 34492709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (6-month, thrice weekly, moderate-vigorous intensity cycling)
Number of subjects: 0
Study 34492709 — intervention group
Group type: COMPARATOR
Intervention: Stretching (control group)
Number of subjects: 0
Study 34492709 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 0
Study 32209015 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT (n = 403)
Number of subjects: 810
Study 32209015 — intervention group
Group type: COMPARATOR
Intervention: MCV4-DT (Menactra®) (n = 407)
Number of subjects: 810
Study 32209015 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT and MCV4-DT
Number of subjects: 810
Study 35317764 — intervention group
Group type: EXPERIMENTAL
Intervention: eHealth patient education tool
Number of subjects: 216
Study 35317764 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study 33050952 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Emotional‐Cognitive Therapy (SECT)
Number of subjects: 300
Study 33050952 — intervention group
Group type: COMPARATOR
Intervention: Emotion‐Focused Supportive Therapy (EFST)
Number of subjects: 300
Study 34534489 — intervention group
Group type: EXPERIMENTAL
Intervention: Second BCG vaccination
Number of subjects: 47000
Study 32738573 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsule (PC)
Number of subjects: 35
Study 32738573 — intervention group
Group type: COMPARATOR
Intervention: Control capsule (CC)
Number of subjects: 35
Study 35296055 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized computerized cognitive stimulation program, 8 weeks, training 5 days per week
Number of subjects: 60
Study 35296055 — intervention group
Group type: COMPARATOR
Intervention: Orthogonal activities (active control group)
Number of subjects: 60
Study 32115671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound multimodal score in the AA group
Number of subjects: 138
Study 32115671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 138
Study 35642463 — intervention group
Group type: EXPERIMENTAL
Intervention: Gla + 2-3 OADs
Number of subjects: 384
Study 35642463 — intervention group
Group type: COMPARATOR
Intervention: Asp30 + MET
Number of subjects: 384
Study 35355062 — intervention group
Group type: EXPERIMENTAL
Intervention: Preimplantation genetic testing for aneuploidy (PGT-A)
Number of subjects: 0
Study 35355062 — intervention group
Group type: COMPARATOR
Intervention: Non-use of preimplantation genetic testing for aneuploidy (PGT-A)
Number of subjects: 0
Study 34465356 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-aided rehabilitation (experimental group, n = 10)
Number of subjects: 23
Study 34465356 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitative protocol (control group, n = 13)
Number of subjects: 23
Study 34898136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular nerve stimulation for 90 days
Number of subjects: 30
Study 34898136 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 90 days
Number of subjects: 30
Study 33538178 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin α1
Number of subjects: 0
Study 32345294 — intervention group
Group type: EXPERIMENTAL
Intervention: High social capital
Number of subjects: 536
Study 32345294 — intervention group
Group type: COMPARATOR
Intervention: Low social capital
Number of subjects: 536
Study 33999371 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of parathyroid hormone (PTH) in patients with positive histology for hepatic fibrosis, steatosis, and NASH/NAFLD
Number of subjects: 90
Study 33999371 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of PTH in patients with liver fibrosis confirmed by elastography
Number of subjects: 90
Study 33999371 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of PTH with hepatic fibrosis, NASH, and steatosis
Number of subjects: 90
Study 34154353 — intervention group
Group type: EXPERIMENTAL
Intervention: ICF concept rehabilitation training
Number of subjects: 142
Study 34154353 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation training (Control)
Number of subjects: 142
Study 32715961 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic ovarian cancer patients
Number of subjects: 2991
Study 32715961 — intervention group
Group type: COMPARATOR
Intervention: Matched controls without cancer
Number of subjects: 2991
Study 33427425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepuncture flow-mediated dilation (FMD [+])
Number of subjects: 222
Study 33427425 — intervention group
Group type: COMPARATOR
Intervention: No prepuncture flow-mediated dilation (FMD [-])
Number of subjects: 222
Study 32862256 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine tampon
Number of subjects: 87
Study 32862256 — intervention group
Group type: COMPARATOR
Intervention: Monoject® syringe
Number of subjects: 87
Study 35780390 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression (IPC)
Number of subjects: 6
Study 35780390 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Number of subjects: 6
Study 35780390 — intervention group
Group type: COMPARATOR
Intervention: Control sessions (no interventions)
Number of subjects: 6
Study 35780390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance measurements across oedematous tissue
Number of subjects: 6
Study 36417812 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-immersive virtual reality (VR) training, 3 times a week for 8 weeks.
Number of subjects: 106
Study 36417812 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy (Control group).
Number of subjects: 106
Study 33403549 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal oxygen (HFNO)
Number of subjects: 0
Study 33403549 — intervention group
Group type: COMPARATOR
Intervention: Conventional nasal cannula
Number of subjects: 0
Study 32312273 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive hyperemia peripheral arterial tonometry (RH‐PAT)
Number of subjects: 157
Study 36116147 — intervention group
Group type: COMPARATOR
Intervention: Acellular carbohydrate sources (e.g., flour‐based whole‐grain products)
Number of subjects: 193
Study 36116147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular carbohydrate sources (minimally processed foods with intact cellular structures such as fruits, potatoes/tubers, and rice)
Number of subjects: 193
Study 36116147 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate high-fat (LCHF) principles
Number of subjects: 193
Study 34868475 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE intervention (7 group sessions for children, 3 group sessions for caregivers)
Number of subjects: 59
Study 34868475 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 59
Study 34467454 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram model combining radiomics signatures and clinical factors
Number of subjects: 203
Study 34467454 — intervention group
Group type: COMPARATOR
Intervention: Radiomics model
Number of subjects: 203
Study 34467454 — intervention group
Group type: COMPARATOR
Intervention: Clinical model
Number of subjects: 203
Study 34467454 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics nomogram model
Number of subjects: 203
Study 33940435 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of accurate and focused information about COVID-19 via phone
Number of subjects: 0
Study 33940435 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 33196485 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oral refeeding (IORF) - low-fat-solid diet initiated immediately after hospital admission
Number of subjects: 131
Study 33196485 — intervention group
Group type: COMPARATOR
Intervention: Conventional oral refeeding (CORF) - progressive oral diet restarted when clinical and laboratory parameters improved
Number of subjects: 131
Study 33196485 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate oral refeeding (IORF)
Number of subjects: 131
Study 32560724 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 2 mg
Number of subjects: 1155
Study 32560724 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar 4 mg
Number of subjects: 1155
Study 32560724 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone 30 mg
Number of subjects: 1155
Study 32560724 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar (2 mg and 4 mg) and Pioglitazone
Number of subjects: 1155
Study 35385141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold spray
Number of subjects: 195
Study 35385141 — intervention group
Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 195
Study 35385141 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 195
Study 35385141 — intervention group
Group type: COMPARATOR
Intervention: Cold spray placebo
Number of subjects: 195
Study 35385141 — intervention group
Group type: COMPARATOR
Intervention: ShotBlocker placebo
Number of subjects: 195
Study 33594488 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Insulin
Number of subjects: 0
Study 33594488 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Insulin
Number of subjects: 0
Study 32898188 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at 30 Hz for 20 minutes
Number of subjects: 0
Study 32898188 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at 30 Hz
Number of subjects: 0
Study 35901330 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (51.8% of patients), with paclitaxel/carboplatin as the most common regimen.
Number of subjects: 259
Study 32731214 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐BLI only
Number of subjects: 128
Study 32731214 — intervention group
Group type: COMPARATOR
Intervention: M‐BLI with biopsy confirmation (M‐BLI‐BC)
Number of subjects: 128
Study 35398872 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based nursing intervention (ANI) for 2 months
Number of subjects: 54
Study 35398872 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 33427969 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive jumps countermeasure (JUMP)
Number of subjects: 20
Study 33427969 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 20
Study 32701928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 2%
Number of subjects: 20
Study 32701928 — intervention group
Group type: COMPARATOR
Intervention: Articaine 4%
Number of subjects: 20
Study 32701928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both anesthetics
Number of subjects: 20
Study 35287698 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone + naloxone (up to 20 mg per day)
Number of subjects: 0
Study 35287698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34740804 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender in asymptomatic patients undergoing CEA or CAS
Number of subjects: 106568
Study 34740804 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender in symptomatic patients
Number of subjects: 106568
Study 34740804 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients <75yo
Number of subjects: 106568
Study 34740804 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients ≥75yo
Number of subjects: 106568
Study 34740804 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender in asymptomatic patients undergoing CEA
Number of subjects: 106568
Study 34740804 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender in symptomatic patients undergoing CEA
Number of subjects: 106568
Study 34740804 — intervention group
Group type: COMPARATOR
Intervention: Female gender in patients undergoing CAS
Number of subjects: 106568
Study 36300713 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum interleukin 2 receptor (sIL‐2R) levels
Number of subjects: 340
Study 34863253 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study exploring patient and health worker experiences
Number of subjects: 26
Study 34863253 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions with patients, nurses, and counsellors
Number of subjects: 26
Study 33247722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion (0.2 and 5 ng min‐1 [L leg volume]‐1 for 10 minutes)
Number of subjects: 26
Study 33247722 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldosterone infusion with coinfusion of NAC (125 mg kg‐1 hour‐1 followed by 25 mg kg‐1 hour‐1)
Number of subjects: 26
Study 33247722 — intervention group
Group type: COMPARATOR
Intervention: Aldosterone infusion (both groups)
Number of subjects: 26
Study 32588971 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving amyloid positron emission tomography results
Number of subjects: 164